Evidence map›Paper›PMID 38991038›Full record

ArticlePLoS neglected tropical diseases2024

Plasmodium vivax genomic surveillance in the Peruvian Amazon with Pv AmpliSeq assay.

Johanna Helena Kattenberg, Luis Cabrera-Sosa, Erick Figueroa-Ildefonso, Mathijs Mutsaers, Pieter Monsieurs, Pieter Guetens, Berónica Infante, Christopher Delgado-Ratto, Dionicia Gamboa, Anna Rosanas-Urgell

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. UnderstandingiScience · 2026
    Article
  4. Article
  5. Article
  6. UnderstandingmedRxiv : the preprint server for health sciences · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Johanna Helena KattenbergMalariology Unit, Biomedical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.ORCID 0000-0002-2971-5136
Luis Cabrera-SosaInstituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
Erick Figueroa-IldefonsoInstituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
Mathijs MutsaersMalariology Unit, Biomedical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.
Pieter MonsieursMalariology Unit, Biomedical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.
Pieter GuetensMalariology Unit, Biomedical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.
Berónica InfanteInstituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
Christopher Delgado-RattoMalaria Research Group (MaRCH), Global Health Institute, Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
Dionicia GamboaInstituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano Heredia, Lima, Peru.
Anna Rosanas-UrgellMalariology Unit, Biomedical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium.

Funding

Belgium Development Cooperation (DGD) FA4 PERU, 2017–2021Belgium Development Cooperation (DGD) FA5 PERU, 2022–2026VLIR-UOS PE2018TEA470A102
6 · The paper itself

Abstract

backgroundPlasmodium vivax is the most predominant malaria species in Latin America, constituting 71.5% of malaria cases in 2021. With several countries aiming for malaria elimination, it is crucial to prioritize effectiveness of national control programs by optimizing the utilization of available resources and strategically implementing necessary changes. To support this, there is a need for innovative approaches such as genomic surveillance tools that can investigate changes in transmission intensity, imported cases and sources of reintroduction, and can detect molecular markers associated with drug resistance. METHODOLOGY/PRINCIPAL

findingsHere, we apply a modified highly-multiplexed deep sequencing assay: Pv AmpliSeq v2 Peru. The tool targets a newly developed 41-SNP Peru barcode for parasite population analysis within Peru, the 33-SNP vivaxGEN-geo panel for country-level classification, and 11 putative drug resistance genes. It was applied to 230 samples from the Peruvian Amazon (2007-2020), generating baseline surveillance data. We observed a heterogenous P. vivax population with high diversity and gene flow in peri-urban areas of Maynas province (Loreto region) with a temporal drift using all SNPs detected by the assay (nSNP = 2909). In comparison, in an indigenous isolated area, the parasite population was genetically differentiated (FST = 0.07-0.09) with moderate diversity and high relatedness between isolates in the community. In a remote border community, a clonal P. vivax cluster was identified, with distinct haplotypes in drug resistant genes and ama1, more similar to Brazilian isolates, likely representing an introduction of P. vivax from Brazil at that time. To test its applicability for Latin America, we evaluated the SNP Peru barcode in P. vivax genomes from the region and demonstrated the capacity to capture local population clustering at within-country level. CONCLUSIONS/SIGNIFICANCE: Together this data shows that P. vivax transmission is heterogeneous in different settings within the Peruvian Amazon. Genetic analysis is a key component for regional malaria control, offering valuable insights that should be incorporated into routine surveillance.

Indexed as

Malaria, VivaxPlasmodium vivaxPolymorphism, Single NucleotideDrug ResistanceEpidemiological MonitoringGenome, ProtozoanGenomicsHigh-Throughput Nucleotide SequencingHumansPeru

Identifiers

PMID38991038
PMCPMC11265702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.